Sample of synthetic peptide vaccine SPf66, developed by Dr Patarroyo and collaborators as a synthetic vaccine for malaria, Bogota, Colombia, with placebo, as used in the Phase III randomised, double-blind, placebo controlled trial at La Tola, Colombia, 1992. (The Lancet, 20 March 1993)
Sample of synthetic peptide vaccine SPf66, developed by Dr Manuel Elkin Patarroyo and collaborators as a synthetic vaccine for malaria, Bogota, Colombia, with placebo, as used in the Phase III randomised, double-blind, placebo controlled trial at La Tola, Colombia, 1992. (The Lancet, 20 March 1993)
Sample of synthetic peptide vaccine SPf66, developed by Dr Manuel Elkin Patarroyo and collaborators as a synthetic vaccine for malaria, Bogota, Colombia, with placebo, as used in the Phase III randomised, double-blind, placebo controlled trial at La Tola, Colombia, 1992. (The Lancet, 20 March 1993)
Sample of synthetic peptide vaccine SPf66, developed by Dr Manuel Elkin Patarroyo and collaborators as a synthetic vaccine for malaria, Bogota, Colombia, with placebo, as used in the Phase III randomised, double-blind, placebo controlled trial at La Tola, Colombia, 1992. (The Lancet, 20 March 1993)
